Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Editas Medicine (EDIT)

Editas Medicine (EDIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Editas: Q3 Earnings Snapshot AP - Mon Nov 10, 6:24AM CST

Editas: Q3 Earnings Snapshot

EDIT : 2.42 (-0.41%)
Editas Medicine Announces Third Quarter 2025 Results and Business Updates GlobeNewswire - Mon Nov 10, 6:00AM CST

In vivo  preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy ...

EDIT : 2.42 (-0.41%)
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 GlobeNewswire - Mon Nov 3, 8:00AM CST

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 2.42 (-0.41%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush BayStreet.ca - Thu Oct 16, 8:23AM CDT

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.5500 (-1.27%)
AVAI : 0.2875 (-2.58%)
DNLI : 19.96 (-0.75%)
EDIT : 2.42 (-0.41%)
XNCR : 17.30 (-4.63%)
Editas Medicine Unveils Promising Preclinical Data on EDIT-401 Tipranks - Fri Oct 10, 4:00PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Editas Medicine...

EDIT : 2.42 (-0.41%)
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress GlobeNewswire - Thu Oct 9, 10:01AM CDT

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported  in vivo preclinical proof-of-concept data for EDIT-401,...

EDIT : 2.42 (-0.41%)
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences GlobeNewswire - Mon Oct 6, 8:00AM CDT

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...

EDIT : 2.42 (-0.41%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus PR Newswire - Thu Sep 25, 8:15AM CDT

USA News Group News Commentary

VCYT : 44.61 (-5.91%)
QURE : 21.33 (-6.20%)
HUM : 257.85 (+1.91%)
AVAI : 0.2875 (-2.58%)
EDIT : 2.42 (-0.41%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus Newswire.ca - Thu Sep 25, 8:15AM CDT

/CNW/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...

VCYT : 44.61 (-5.91%)
HUM : 257.85 (+1.91%)
QURE : 21.33 (-6.20%)
AVAI : 0.2875 (-2.58%)
EDIT : 2.42 (-0.41%)
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate GlobeNewswire - Tue Sep 2, 6:00AM CDT

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway...

EDIT : 2.42 (-0.41%)

Barchart Exclusives

Most “Safe” Dividend Stocks Don’t Grow Like This… But These 3 Did Barchart - 1 hour ago
Three Dividend Kings Wall Street rates “Strong Buy”, supported by strong five-year earnings growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot